PTHS Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. (PTHS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $16.9K.
Where they traded
Last open-market purchase: June 11, 2026 , by Davis Todd C .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Greenleaf Peter | Director | Sell 10b5-1 | 797 | $21.17 | $16.9K | 23,087 −3.3% of holding | |
| Pauls Matthew | Director | Sell 10b5-1 | 786 | $21.00 | $16.5K | 13,578 −5.5% of holding | |
| Friedberg Ezra M | Director | Sell 10b5-1 | 558 | $20.72 | $11.6K | 80,484 −0.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.